Will We Ever Know the Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation?⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.  by Kastrati, Adnan et al.
e
e
a
t
D
B
C
r
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 4 , N O . 1 0 , 2 0 1 1
© 2 0 1 1 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 1 . 0 8 . 0 0 3EDITORIAL COMMENT
Will We Ever Know
the Optimal Duration of
Dual Antiplatelet Therapy
After Drug-Eluting
Stent Implantation?*
Adnan Kastrati, MD, Robert A. Byrne, MBBCH,
Stefanie Schulz, MD
Munich, Germany
Drug-eluting stents (DES) have emerged as the most
effective means to reduce restenosis after percutaneous
coronary intervention (PCI) (1,2). However, high antirest-
enotic efficacy in comparison with bare-metal stents (BMS)
is achieved at the expense of a delay in healing of the stented
arterial segment (3). Although meta-analyses of randomized
trials could not confirm initial reports concerning a higher
overall risk of stent thrombosis with DES compared with
BMS (4–6), there seems to be a different distribution of
vents over time with a tendency toward more thrombotic
vents with BMS early after PCI and an excess of events
See page 1119
very late after PCI with DES. Although there is no doubt
about the value of periprocedural thienopyridine therapy in
addition to aspirin to reduce early stent thromboses (7), it is
not known whether the risk of very late stent thromboses
can be mitigated by prolonged dual antiplatelet therapy
(DAPT). At the heart of the dilemma facing the practicing
clinician is a lack of solid evidence as to when it is safe to
discontinue clopidogrel therapy after DES implantation.
This uncertainty is mirrored in the guidelines of the major
cardiac societies on both sides of the Atlantic. Whereas, in
2007, American cardiac and noncardiac societies issued a
joint statement that all patients with DES implantation
should receive clopidogrel therapy for at least 12 months if
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myocardial revascularization of the European Society of
Cardiology explicitly state that convincing data for contin-
uation of DAPT exist only up to 6 months after interven-
tion, and accordingly recommend a duration of 6 to 12
months (9).
Importantly, we should remember that the questions
surrounding the optimal duration of DAPT is not restricted
to intervention with DES. Indeed, this issue has also been the
focus of several studies in the BMS era. In the PCI–CURE
(Percutaneous Coronary Intervention–Clopidogrel in Unstable
angina to prevent Recurrent Events) substudy of the CURE
trial (10), there was a 31% relative risk reduction in ischemic
events following an extension of clopidogrel therapy for a mean
of 8months beyond the standard 4-week treatment after BMS.
However, the reduction in ischemic events in the main
CURE trial (11) occurred at the expense of a 38% increased
risk of major bleedings. The CREDO (Clopidogrel for the
Reduction of Events During Observation) trial investigators
also reported a significant reduction in ischemic events in
patients undergoing elective PCI who received clopi-
dogrel for up to 12 months, although again there was a
clear signal toward an excess of major bleeding (12). It
should be noted, however, that both these trials tested a
dual strategy of clopidogrel loading plus therapy prolon-
gation versus no loading plus standard therapy. There-
fore, the reduction in ischemic events cannot be ascribed
to clopidogrel therapy prolongation alone. Indeed, the
optimal duration of DAPT after BMS remains very much
an unresolved question.
In this issue of JACC: Cardiovascular Interventions,
Kandzari et al. (13) address the unmet clinical need con-
cerning the most appropriate duration of DAPT after DES
implantation. They performed a pooled analysis of 1,414 of
2,032 patients enrolled in 5 pivotal trials of the zotarolimus-
eluting Endeavor stent (Medtronic, Minneapolis, Minne-
sota) who were both event-free and on DAPT at 6 months
after DES implantation. Outcome comparisons were per-
formed relative to DAPT duration: 6, 12, or 24 months.
After 3 years of follow-up, there was neither a difference in
the composite ischemic endpoint of death, myocardial
infarction, stroke, and stent thrombosis nor in its individual
components. The investigators should be commended for
using prospectively collected data with an acceptable length
of follow-up and for including consideration of bleeding
endpoints, which show considerable prognostic value in
patients undergoing PCI (14) but have been neglected by
many other clinical studies. In fact, no bleeding event was
detected in any patient throughout the follow-up. This may
be related to the circumstance that the trials included in the
present analysis were device trials with primary focus on
stent-related outcomes rather than on bleeding, as well as to
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1130the challenges involved in detecting bleeding during long-
term follow-up. In addition, the investigators of the present
study defined bleeding as the need for blood transfusion, a
conservative definition that may fail to account for the entire
spectrum of this complication.
The findings of the present study are in line with those of
previous observational studies in suggesting no need for a
DAPT duration beyond 6 months (15–17). However, in
interpreting the data, some limitations must be considered.
First and foremost, the study of Kandzari et al. (13) suffers
from the limitation of selection bias, inherent to all studies
not specifically designed a priori to evaluate optimal DAPT
duration in patients treated with DES. The patients who
continued clopidogrel for 12 months or longer in the
present study were clearly sicker than the patients with 6
months of clopidogrel therapy. The ability of statistical
methods, including propensity score analysis to fully adjust
for these imbalances is questionable. It could be speculated
that outcomes for patients with longer clopidogrel duration
would have been worse if they had stopped clopidogrel
intake earlier. Second, the exclusion of high-risk patients
from this series is a typical feature of device-approval trials,
such as those included in the present analysis. The issue of
optimal duration of DAPT might be even more critical for
these higher-risk patients. Third, the findings of Kandzari
et al. (13) relate to a DES type that outside of the United
States is largely replaced by its successor—the Endeavor
Resolute stent (Medtronic Inc., Santa Rosa, California).
However, these issues notwithstanding, the data presented
represent a relevant contribution to the efforts to explore the
issue of optimal duration of DAPT after DES implantation.
Despite the abundance of data from observational studies,
such studies cannot serve to guide current practice regarding
the optimal duration of DAPT in patients receiving DES,
in view of the serious limitations inherent to nonrandom-
ized investigations. Recently, the results of 2 completed
open-label, randomized trials have been published or pre-
sented at cardiology meetings. In the trial of Park et al. (18),
2,701 patients treated with DES were randomly assigned
either to stop clopidogrel after 12 months or to continue it
beyond 12 months. With only 32 patients reaching the
primary ischemic endpoint and 4 patients incurring major
bleeding during a median follow-up of 19.2 months, the
study was not able to show significant differences in out-
comes between the 2 treatment strategies (18). In the trial of
Gwon et al. (19), 1,443 patients were randomly allocated to
1 of the 2 study arms: 6- or 12-month duration of
clopidogrel. This study also failed to detect significant
differences in outcomes related to the duration of clopi-
dogrel therapy. However, although these 2 relatively small-
sized trials suggest no clear need for continuing DAPT
beyond 6 to 12 months, the case of optimal duration of
DAPT after DES is far from being closed. A number of
ongoing large-scale randomized clinical trials (Table 1) areaddressing this issue, and their results will be eagerly
awaited over the coming years.
However, studies aimed at the evaluation of optimal
duration of DAPT after DES face several common prob-
lems that may prevent their results from generating recom-
mendations valid for all patients treated with DES. First,
the incidence of both stent thrombosis and bleeding de-
creases drastically after 6 to 12 months post procedure.
Finding a reasonable, statistically founded balance to guide
timing of discontinuation of DAPT may require enrollment
of many thousands of patients. This number may not be met
by ongoing and future clinical trials. Second, it will be
difficult to differentiate between the effects of DAPT on
stent-related outcomes versus atherothrombotic events oc-
curring outside the stented segments. A subgroup analysis
from the CHARISMA (Clopidogrel for High Athero-
thrombotic Risk and Ischemic Stabilization, Management,
and Avoidance) trial (20) suggested that continued DAPT
with clopidogrel and aspirin might reduce ischemic events
in patients with clinically evident atherothrombosis com-
pared with aspirin monotherapy even in the absence of PCI.
Thus, any observed benefit with prolongation of DAPT
might not be related to the presence of DES per se. Third,
overall study results may not reflect the specific needs of
different subsets of patients. Although it has never been
definitively shown that patients with acute coronary syn-
dromes (ACS) need DAPT for 6 months, recent clinical
trials on antiplatelet therapy in patients with ACS have
deliberately chosen a treatment period of at least 12 months
irrespective of whether PCI was performed. Thus, the
duration of DAPT is currently driven by the instability of
disease presentation rather than by the type of stent received
by the patient. It will be hard for the ongoing trials on
DAPT duration after DES to change this practice. Fourth,
an increasing knowledge of factors associated with higher
risk of stent thrombosis (thrombus-containing lesions, bi-
furcation lesions, long lesions, long stented segments, sub-
optimal procedural results, and so on) or bleeding (older
age, low body mass index, hypertension, nephropathy,
history of stroke, and so on) may induce physicians to tailor
DAPT duration to these factors rather than to rely on the
results derived from the entire study cohort of ongoing
clinical trials. Fifth, different DES devices may confer
different risks of late stent thrombosis (21,22). Newer,
biodegradable polymer-based (23,24) or polymer-free DES
(25) may also have an impact on the late risk of stent
thrombosis in a way that cannot be accounted for in ongoing
DAPT trials. Sixth, there is an increasing hope that novel
imaging technologies such as optical coherence tomography
may provide useful information regarding necessary dura-
tion of DAPT based on the quality of DES strut coverage
at follow-up imaging. Ongoing DAPT trials may be miss-
ing this potential. Finally, new adenosine diphosphate–
receptor antagonists—prasugrel and ticagrelor—have re-
let Ther
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1131cently been approved for use in patients with ACS.
Although their superiority over clopidogrel has been estab-
lished in a large percentage of ACS patients (26,27), it is
still not known how this might influence the duration of
DAPT after DES.
Although the study of Kandzari et al. (13) provides some
further reassurance that a 6-month duration of clopidogrel
treatment might be safe in certain patients treated with a
particular type of DES, the optimal duration of DAPT to
be used in patients who receive DES remains unknown.
Ongoing randomized trials will certainly help in defining
some time limits for treatment duration, yet, they will not be
able to delineate a length of therapy appropriate for all
DES-treated patients. Optimal DAPT duration after DES
will still be guided by a careful assessment of the balance
between the risk of stent thrombosis and the likelihood of
bleeding events at an individual patient level.
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Table 1. Ongoing Randomized Clinical Trials on the Duration of DAPT After
Study Sample Size
DAPT Duration
(Months) Masking Stent Type
DAPT 20,645 12 vs. 30 Double-blind DES (n  15,24
BMS (n  5,
ISAR-SAFE 6,000 6 vs. 12 Double-blind DES
DES-LATE 5,000 12 vs. 12 Open-label DES
SECURITY 4,000 6 vs. 12 Open-label Endeavor
Resolute
ITALIC 3,200 6 vs. 6 Open-label Xience
OPTIMIZE 3,120 3 vs. 12 Open-label Endeavor
ARCTIC 2,500 12 vs. 18–30 Open-label DES
PRODIGY 1,970 1 (BMS)/6 (DES) vs. 24 Open-label BMS, ZES, PES,
(1:1:1:1)
OPTIDUAL 1,966 12 vs. 36 Open-label DES
SCORE 280 12 vs. 24 Open-label DES
ARCTIC  Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Co
Antiplatelet Therapy, One Year After Stenting; BMS bare-metal stent(s); DAPT dual antiplatelet
of Drug-Eluting Stents; EES everolimus-eluting stent(s); ISAR-SAFE Safety and Efficacy of Six Mo
After Discontinuation of Clopidogrel; MImyocardial infarction; OPTIDUALOptimal Duration of
With Contrast on the Diagnostic Accuracy of Dobutamine Echocardiography in Coronary Artery
ProlongingDual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study; SCO
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